News News

June 24, 2021 Sirnaomics Doses First Patient in Phase 1 Clinical Study of STP705 for Treatment of Liver Cancer

Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical company engaged…

June 16, 2021 Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic…

April 28, 2021 Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702

Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery…

April 26, 2021 Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Company Expects to Report Initial Clinical Data in Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical company…

April 21, 2021 Sirnaomics’ Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today…

April 18, 2021 Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

Company Expects to Report Interim Clinical Data in the Second Half of 2021 Sirnaomics, Inc., a biopharmaceutical…

1 2 3 4 12